Creo Medical Group PLC represents values such as innovation, integrity, and excellence. The company is dedicated to delivering cutting-edge medical solutions to improve patient outcomes. Creo Medical Group PLC follows a patient-centric approach, ensuring that their products and technologies meet the highest standards of quality and effectiveness. Their corporate philosophy emphasizes the importance of collaboration, research, and development to provide advanced therapeutic solutions in the field of endoscopy and minimally invasive surgery. With a strong focus on continuous improvement and customer satisfaction, Creo Medical Group PLC strives to contribute to the advancement of medical technology for the benefit of patients worldwide.

Creo Medical Group PLC is primarily present in various countries and regions around the world. Some of the key markets where the company operates include the United Kingdom, Europe, Asia-Pacific, and North America. With its global presence, Creo Medical Group PLC caters to a wide range of customers and investors across different geographical locations.

Creo Medical Group PLC has achieved significant milestones since its establishment. Some noteworthy achievements include the FDA clearance for their Speedboat RS2 device, allowing the company to enter the US market and expand its customer base. Additionally, Creo Medical Group PLC received CE Mark approval for its CROMA platform, enabling commercialization in the European market. The company also secured key partnerships and collaborations with renowned medical institutions and professionals, highlighting its commitment to innovation and development in the medical device sector. With these milestones, Creo Medical Group PLC has established itself as a leading player in the field, dedicated to improving patient outcomes through advanced technology.

Creo Medical Group PLC, a leading medical device company based in the UK, was founded in 2003. The company specializes in the development and commercialization of advanced surgical instruments. Creo Medical has a strong focus on non-invasive surgical technologies that provide effective treatments with minimal patient discomfort and enhanced recovery. With a talented team of professionals, Creo Medical has achieved significant milestones in its history, including the successful launch of its flagship device, the CROMA™ Advanced Energy Platform. The company is committed to driving innovation in the medical field, working towards improving patient outcomes and revolutionizing surgical procedures globally. Creo Medical Group PLC continues to grow and establish a strong presence in the market through its dedication to research, development, and commercialization of cutting-edge medical devices.

The main competitors of Creo Medical Group PLC in the market are (insert competitor names here).

Creo Medical Group PLC is primarily active in the medical technology industry.

The business model of Creo Medical Group PLC revolves around developing and commercializing medical devices for surgical endoscopy. Creo Medical specializes in advanced energy devices and aims to provide innovative solutions for minimally invasive procedures, such as radiofrequency ablation and microwave coagulation. By leveraging its proprietary technology, Creo Medical aims to enable healthcare professionals to improve patient outcomes, minimize complications, and reduce healthcare costs. With a focus on enhancing clinical capabilities and expanding its product portfolio, Creo Medical Group PLC continues to drive innovation in the medical device industry.

Коефициентът на цена спрямо печалбата (КЦП) на Creo Medical Group е -6,56.

Коефициентът на цена към оборот (KUV) на Creo Medical Group е 2,25.

AlleAktien качественият резултат за Creo Medical Group е 5/10.

очаквана Creo Medical Group оборотът е 39,96 млн. GBP.

очаквана Creo Medical Group печалба е -13,72 млн. GBP.

Creo Medical Group PLC is a British medical technology company that specializes in the development and marketing of advanced medical technologies for endoscopy. The company was founded in 2003 and is headquartered in Chepstow, Wales.

Creo Medical Group разпределя дивидента от 0 GBP на плащания годишно.

Дивидентата за Creo Medical Group в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Creo Medical Group е GB00BZ1BLL44.

WKN на Creo Medical Group е A2DH40.

Тикерът на Creo Medical Group е CREO.L.

През последните 12 месеца Creo Medical Group изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Creo Medical Group да изплати дивиденда в размер на 0 GBP.

Дивидентната доходност на Creo Medical Group в момента е .

Creo Medical Group изплаща дивидент на тримесечие. Той се разпределя в месеците .

Creo Medical Group платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 GBP. Това съответства на дивидентна доходност от 0 %.

Creo Medical Group се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Creo Medical Group на 11.09.2024 г. в размер на 0 GBP, трябваше да притежавате акцията в портфейла си преди Ex-деня на 11.09.2024 г..

Последното дивидентно плащане беше извършено на 11.09.2024 г..

През година 2023 Creo Medical Group изплати 0 GBP под формата на дивиденти.

Дивидентите от Creo Medical Group се изплащат в GBP.